Detalhe da pesquisa
1.
Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, Phase 3 trial.
Diabetes Obes Metab
; 22(6): 957-968, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32003150
2.
Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes.
Diabetes Obes Metab
; 22(7): 1094-1101, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32072735
3.
Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial.
Diabetes Obes Metab
; 22(7): 1083-1093, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32052516
4.
Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes.
Diabetes Obes Metab
; 21(9): 2152-2162, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31144431
5.
Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.
Diabetes Obes Metab
; 21(4): 883-892, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30499237
6.
Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin.
Diabetes Obes Metab
; 20(6): 1542-1546, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29446523
7.
Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes.
Diabetes Obes Metab
; 20(11): 2598-2607, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29947099
8.
Patient perceptions of their glycemic control and its influence on type 2 diabetes outcomes: an international survey of online communities.
Patient Prefer Adherence
; 13: 295-307, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30863019
9.
The patient's perspective of computerised records: a questionnaire survey in primary care.
Inform Prim Care
; 16(2): 93-9, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18713525
10.
Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin.
Arch Endocrinol Metab
; 62(4): 424-430, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30304106
11.
Elevated Potassium Levels in Patients With Congestive Heart Failure: Occurrence, Risk Factors, and Clinical Outcomes: A Danish Population-Based Cohort Study.
J Am Heart Assoc
; 7(11)2018 05 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-29789332
12.
Characterization of the Open-Label Lead-In Period of Two Randomized Controlled Phase 3 Trials Evaluating Dapagliflozin, Saxagliptin, and Metformin in Type 2 Diabetes.
Diabetes Ther
; 9(4): 1703-1711, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-29802530
13.
Quality of life and satisfaction with treatment in subjects with type 2 diabetes: results in Spain of the PANORAMA study.
Endocrinol Nutr
; 61(1): 18-26, 2014 Jan.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-24055176
14.
Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin
Arch. endocrinol. metab. (Online)
; 62(4): 424-430, July-Aug. 2018. tab, graf
Artigo
em Inglês
| LILACS | ID: biblio-950077
15.
Calidad de vida y satisfacción con el tratamiento de sujetos con diabetes tipo 2: resultados en España del estudio PANORAMA / Quality of life and satisfaction with treatment in subjects with type 2 diabetes: Results in Spain of the PANORAMA study
Endocrinol. nutr. (Ed. impr.)
; 61(1): 18-26, ene. 2014. graf, tab
Artigo
em Espanhol
| IBECS (Espanha) | ID: ibc-118265